Article Data

  • Views 232
  • Dowloads 0

Original Research

Open Access

Prenatal and postnatal risk factors for developing bronchopulmonary dysplasia


1Division of Perinatology, Department of Obstetrics and Gynecology University Medical Center Ljubljana

2Division of Pathology, Department of Obstetrics and Gynecology University Medical Center Ljubljana

3,nstitute of Microbiology and Immunology Medical faculty Ljubljana

DOI: 10.22514/SV62.102011.6 Vol.6,Issue 2,October 2011 pp.46-51

Published: 31 October 2011

*Corresponding Author(s): IRENA ŠTUCIN GANTAR E-mail:


Aim. To determine prenatal and postnatal risk factors for developing bronchopulmonary dysplasia in infants < 30 weeks of gestational age.

Methods. Over a 22-month period, 115 newborns were enrolled in the study. Details including gestational age, sex, birth weight, prenatal steroids, surfactant treatment, ventilatory support, days of postnatal oxygen requirement, late onset sepsis/pneumonia, air leaks, patency of ductus arteriosus, and fluid intake were collected. The presence of chorioamnionitis was diagnosed by histological examination. Commercial ELISA kits were used for the determination of the IL-6 and IL-8 levels. Results. Twenty-five infants developed BPD and 90 were enrolled in the non BPD group. Lower gestational age and male sex increased the risk for BPD. There was no difference in the presence of chorioamnitis and the level of IL-6 and IL-8 measured in cord blood and gastric aspirate between the groups. Intubation in the delivery room (resuscitation), need for surfactant treatment, mechanical ventilation, late onset sepsis/pneumonia, increased oxygenation index increased the risk for BPD after adjustment for GA and gender.

Conclusion. In our cohort of infants with GA < 30 weeks exposure to prenatal inflammation did not increase the risk for BPD. However, low gestational age, male sex, need for resuscitation, mechanical ventilation and late onset sepsis were major risk factors for BPD development.


premature infant, bron-chopulmonary dysplasia, respiratory distress syndrome, chorioamnionitis, interleukin 6, interleukin 8

Cite and Share

IRENA ŠTUCIN GANTAR ,JANEZ BABNIK,LILIJANA KORNHAUSER CERAR,JASNA ŠINKOVEC,BRANKA WRABER. Prenatal and postnatal risk factors for developing bronchopulmonary dysplasia. Signa Vitae. 2011. 6(2);46-51.


1. Northway WH, Rosan RC, Porter DY. Pulmonary disease following respiratory therapy of hyaline membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967;276:357􀀁68.

2. Gonzalez A, Sosenko IR, Chandar J, Hummler H, Claure N, Bancalari E. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatr. 1996;128:470􀀁78.

3. Rojas MA, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Neto G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr. 1995;126:605􀀁10.

4. Speer CP. Pre- and postnatal inflammatory mechanisms in chronic lung disease of preterm infants. Paed Resp Rev. 2004;5:241􀀁44.

5. Watterberg KL, Demers LM, Scott SM, Murphy S. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics. 1996;97:210􀀁15.

6. Hitti J, Krohn MA, Patton DL, Tarczy-Hornoch P, Hillier SL, Cassen EM, et al. Amniotic fluid tumor necrosis factor-alpha and the risk of respiratory distress syndrome among preterm infants. Am J Obstet Gynecol. 1997;177:50􀀁6.

7. Ohyama M, Itani Y, Yamanaka M, Goto A, Kato K, Ijiri R, et al. Re-evaluation of chorioamnionitis and funisitis with a special reference to subacute chorioamnionitis. Hum Pathol. 2002;33:183􀀁90.

8. Ogunyemi D, Murillo M, Jackson U, Hunter N, Alperson B. The relationship between placental histopathology findings and perinatal out-come in preterm infants. J Matern Fetal Neonatal Med. 2003;13:102􀀁9.

9. Matsuda T, Nakajima T, Hattori S, Hanatani K, Fukazawa Y, Kobayashi K, et al. Necrotizing funisitis: clinical significance and association with chronic lung disease in premature infants. Am J Obstet Gynecol. 1997;177:1402􀀁7.

10. Yoon BH, Romero R, Kim KS, Park JS, Ki SH, Kim BI, et al. A systemic fetal inflammatory response and the development of bronchopul-monary dysplasia. Am J Obstet Gynecol. 1999;181:773-9.

11. Mittendorf R, Covert R, Montag AG, elMasri W, Muraskas J, Lee KS, et al. Special relationships between fetal inflammatory response syndrome and bronchopulmonary dysplasia in neonates. J Perinat Med. 2005;33:428􀀁34.

12. Redline RW, Wilson-Costello D, Hack M. Placental and other perinatal risk factors for chronic lung disease in very low birth weight infants. Pediatr Res. 2002;52:713􀀁9.

13. Kent A, Dahlstrom JE. Chorioamnionitis/funisitis and the development of bronchopulmonary dysplasia. J Paediatr Child Health. 2004;40:356􀀁9.

14. Jobe AH. Antenatal factors and the development of bronchopulmonary dysplasia. Semin Neonatol. 2003;8:9􀀁17.

15. Van Marter LJ, Dammann O, Allred EN, Leviton A, Pagano M, Moore M, et al. Chorioamnionitis, mechanical ventilation, and postnatal sepsis as modulators of chronic lung disease in preterm infants. J Peaditr. 2002;140:171􀀁6.

16. Dargaville PA, South M, Vervaart P, McDougall PN. Validity of markers of dilution in small volume lung lavage. Am J Respir Crit Care Med. 1999;160:778􀀁84.

17. Horbar JD, Onstad L, Wright E. The National institute of Child Health and Human Development Neonatal Research Network. Predicting mortality risk for infants weighing 501 to 1500 grams at birth: The National Institutes of Health Neonatal Research Network report. Crit Care Med. 1993;21:12􀀁7.

18. Vento M, Aguar M, Escobar J, Arduini A, Escrig R, Escrig R, et al. Antenatal steroids and antioxidant enzyme activity in preterm infants: influence of gender and timing. Antioxid Redox Signal. 2009;11:2945􀀁55.

19. Willet KE, Kramer BW, Kallapur SG, Ikegami M, Newnham JP, Moss TJ, et al. Intra-amniotic injection of IL-1 induces inflammation and maturation in fetal sheep lung. Am J Physiol. 2002;282:411􀀁20.

20. Lahra MM, Beeby PJ, Jeffery HE. Maternal versus fetal inflammation and respiratory distress syndrome: a 10 year hospital cohort study. Arch Dis Child Fetal Neonatal Ed. 2009:94:13􀀁6.

21. Kaukola T, Tuimala J, Herva R, Kingsmore S, Hallman M. Cord immunoproteins as predictors of respiratory outcome in preterm infants. Am J Obstet Gynecol. 2009;200:100􀀁8.

22. Dempsey E, Chen MF, Kokottis T, Vallerand D, Usher R. Outcome of neonates less than 30 weeks gestation with histologic chorioamnio-nitis. Am J Perinatol. 2005;22:155􀀁9.

23. Kosuge S, Ohkuchi A, Minakami H, Matsubara S, Uchida A, Eguchi Y, et al. Influence of chorioamnionitis on survival and morbidity in singletons live-born at < 32 weeks of gestation. Acta Obstet Gynecol Scand. 2000;79:861􀀁5.

24. Moss TJ, Newnham JP, Willett KE, Kramer BW, Jobe AH, Ikegami M. Early gestational intra-amniotic endotoxin: lung function, surfactant, and morphometry. Am J Respir Crit Care Med. 2002;165:805􀀁11.

25. Bry K, Lappalainen U, Hallman M. Intraamniotic interleukin-1 accelerates surfactant protein synthesis in fetal rabbits and improves lung stability after premature birth. J Clin Invest. 1997;99:2992􀀁9.

26. Kallapur SG, Willet KE, Jobe AH, Ikegami M, Bachurski CJ. Intra-amniotic endotoxin: chorioamnionitis precedes lung maturation in preterm lambs. Am J Physiol. 2001;280:527􀀁36.

27. Jobe AH, Newnham JP, Willet KE, Moss TJ, Gore Ervin M, Padbury JF, et al. Endotoxin-induced lung maturation in preterm lambs is not mediated by cortisol. Am J Respir Crit Care Med. 2000;162:1656􀀁61.

28. Kramer EL, Deutsch GH, Sartor MA, Hardie WD, Ikegami M, Korfhagen TR, et al. Perinatal increases in TGF-{alpha} disrupt the saccular phase of lung morphogenesis and cause remodeling: microarray analysis. Am J Physiol Lung Cell Mol Physiol. 2007;293:214􀀁27.

29. Viscardi RM, Muhumuza CK, Rodriguez A, Fairchild KD, Sun CC, Gross GW, et al. Inflammatory markers in intrauterine and fetal blood and cerebrospinal fluid compartments are associated with adverse pulmonary and neurologic outcomes in preterm infants. Pediatr Res. 2004;55:1009􀀁17.

30. Been JV, Zimmermann LJ. Histological chorioamnionitis and respiratory outcome in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2009;94:18􀀁25.

31. Mu SC, Lin CH, Chen YL, Ma HJ, Lee JS, Lin MI, et al. Impact on neonatal outcome and anthropometric growth in very low birth weight infants with histological chorioamnionitis. J Formos Med Assoc. 2008;107:304􀀁10.

32. Kallapur SG, Nitsos I, Moss TJ, Kramer BW, Newnham JP, Ikegami M, et al. Chronic endotoxin exposure does not cause sustained struc-tural abnormalities in the fetal sheep lungs. Am J Physiol. 2005;288:966􀀁74.

33. Björklund LJ, Ingimarsson J, Curstedt T, Larsson A, Robertson D, Werner O. Lung recruitment at birth does not improve lung function in immature lambs receiving surfactant. Acta Anaesthesiol Scand. 2001;45:986􀀁99.

34. del Moral T, Claure N, Van Buskirk S, Bancalari E. Duration of patent ductus arteriosus as a risk factor for bronchopulmonary dysplasia.Pediatr Res. 2001;49:282A.

35. Gonzalez A, Sosenko IRS, Chandar J, Hummler H, Claure N, Bancalari E. Influence of infection on patent ductus arteriosus and broncho-pulmonary dysplasia in premature infants < 1000g. J Pediatr. 1996;128:470􀀁8.

36. Stephens BE, Gargus RA, Walden RV, Mance M, Nye J, et al. Fluid regimens in the first week of life may increase risk of patent ductus arteriosus in extremely low birth weight infants. J Perinatol. 2008;28:123􀀁8.

37. Ratner V, Slinko S, Utkina-Sosunova I, Starkov A, Polin RA, Ten VS. Hypoxic stress exacerbates hyperoxia-induced lung injury in a neonatal mouse model of bronchopulmonary dysplasia. Neonatology. 2009;95:299􀀁305.

38. Saugstad OD. Bronchopulmonary dysplasia and oxidative stress: are we closer to an understanding of the pathogenesis of BPD? Acta Paediatr. 1997;86:1277􀀁82.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

IndexCopernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time